---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-179062"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T03:56:22.223732+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA grants Breakthrough Therapy Designation to TERN-701; Merck acquisition mentioned in press release

## Summary
- FDA Breakthrough Therapy Designation for TERN-701 in Ph+ CML-CP patients without T315I mutation, previously treated with 2+ TKIs.
- Designation based on CARDINAL Phase 1/2 data: encouraging major molecular response and deep molecular response rates at week 24.
- TERN-701 safety profile: majority of adverse events low grade; low severe adverse events and discontinuations.
- Press release also notes recent agreement for Merck to acquire Terns (Nasdaq: TERN).
- CEO Amy Burroughs cites BTD and Merck deal as potential acceleration to pivotal trial and patients.

## SEC filing metadata
- accession: 0001193125-26-179062
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000119312526179062/0001193125-26-179062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000119312526179062/d122087d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-179062
- JSON: https://secwatch.observer/filing/0001193125-26-179062.json
- Plain text: https://secwatch.observer/filing/0001193125-26-179062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.